Insight

Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.

Collage photo of Ajay Major and Arnaud Amzallag

Nov 20, 2024, 19:12

Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.

Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X about a recent abstract by Arnaud Amzallag, Scientific Associate Director at Bristol Myers Squibb:

“Golcadomide (CELMoD) plus R-CHOP first line LBCL.

Randomized 0.2 vs 0.4 mg in dose expansion
1-yr PFS 85% at 0.4 mg (77% at 0.2)
90% EOT MRD- at 0.4 (73% at 0.2)
better EOT MRD- with 0.4 mg across high-risk genetics

GOLSEEK-1 RCT ongoing with 0.4 mg dose.”

“Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)”

Authors: Arnaud Amzallag, Tara Basavanhally, Jason Westin, Anita Gandhi, Mark Kaplan, et al.

Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.

More posts featuring Ajay Major.

Ajay Major is an Assistant Professor of Medicine at the University of Colorado School of Medicine, specializing in lymphoma and CLL/SLL. He is the Founder and President of Pager Publications, as well as the Founder and Editor-in-Chief of in-House. Additionally, he serves as a Reviewer for the Bellevue Literary Review.

Ajay Major Anita Gandhi Arnaud Amzallag B-cell lymphoma cancer Golcadomide Jason Westin Large B-Cell Lymphoma LBCL Mark Kaplan OncoDaily Oncology R-CHOP Tara Basavanhally

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity